Very High-Risk ASCVD and eligibility for nonstatin therapies based on the 2018 AHA/ACC cholesterol guidelines

Authors

Salim S. Virani, DeBakey Veterans Affairs Medical Center, USA.Follow
JuliaM M. Akeroyd, Baylor College of Medicine, USA.
Sidney C. Smith Jr, University of North Carolina at Chapel Hill, USA.
Mouaz Al-Mallah, Houston Methodist Hospital, USA.
Thomas M. Maddox, University of Colorado School of Medicine
Pamela B. Morris, Medical University of South Carolina, USA.
Laura A. Petersen, Michael E. DeBakey VA Medical Center, USA.
Christie M. Ballantyne, Baylor College of Medicine, USA.
Scott M. Grundy, The University of Texas at Dallas, USA.
Neil J. Stone, Northwestern University, USA.

Document Type

Article

Department

Cardiology; Office of the Provost

Comments

Abstract is not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Journal of the American College of Cardiology

DOI

10.1016/j.jacc.2019.05.051

Recommended Citation

Virani, S. S., Akeroyd, J. M., Smith Jr, S. C., Al-Mallah, M., Maddox, T. M., Morris, P. B., Petersen, L. A., Ballantyne, C. M., Grundy, S. M., Stone, N. J. (2019). Very High-Risk ASCVD and eligibility for nonstatin therapies based on the 2018 AHA/ACC cholesterol guidelines. Journal of the American College of Cardiology, 74(5), 712-714.
Available at: https://ecommons.aku.edu/provost_office/639